Intellia Therapeutics, Inc.

NTLA

Precision medicineBiotech & pharmaceuticals

$12.42vs prev close▼-0.42(-3.27%)

$7.9552W Range$28.25

22% from low

+1.70 (+15.84%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

6 buys

Consecutive buys

1M net buy

+$9.1M

≈ +773K shares

Portfolio Weight

1.10%

1M -0.74%p

Holding ETFs

2 ETFs

ARKG · ARKK

Sell · Weight Down

ARK net-sold the stock and the price fell, decreasing its portfolio weight.

Shares -12.0% · Market value -45.9% · Weight -0.74%p

Trade Intensity

Consecutive buys 6

Basis: 0 sells · 6 buys in 1M · Multi-ETF simultaneous buy · weight -0.74%p decrease

Trade Log6-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.08.21	BUY	ARKG · ARKK	115,499	$12.84	$1.5M
26.08.12	BUY	ARKG · ARKK	13,390	$12.09	$161.9K
26.08.11	BUY	ARKG · ARKK	98,294	$12.02	$1.2M
26.08.10	BUY	ARKG · ARKK	34,271	$12.02	$411.9K
26.08.07	BUY	ARKG · ARKK	89,422	$11.94	$1.1M
26.08.06	BUY	ARKG · ARKK	422,198	$11.24	$4.7M
26.05.12	BUY	ARKK	40,000	$13.99	$559.6K
26.05.11	BUY	ARKK	92,198	$14.42	$1.3M
26.05.08	BUY	ARKK	26,324	$14.09	$370.9K
26.05.07	BUY	ARKK	102,247	$13.71	$1.4M
26.05.06	BUY	ARKK	28,220	$13.85	$390.8K
26.05.05	BUY	ARKK	214,225	$13.31	$2.9M
26.05.01	BUY	ARKK	140,963	$13.26	$1.9M
26.04.29	BUY	ARKG · ARKK	2,407,396	$12.44	$30.0M
26.04.28	BUY	ARKG · ARKK	596,171	$13.20	$7.9M

08.21BUY

115,499

ARKG · ARKKClose$12.84Est. total$1.5M

08.12BUY

13,390

ARKG · ARKKClose$12.09Est. total$161.9K

08.11BUY

98,294

ARKG · ARKKClose$12.02Est. total$1.2M

08.10BUY

34,271

ARKG · ARKKClose$12.02Est. total$411.9K

08.07BUY

89,422

ARKG · ARKKClose$11.94Est. total$1.1M

08.06BUY

422,198

ARKG · ARKKClose$11.24Est. total$4.7M

05.12BUY

40,000

ARKKClose$13.99Est. total$559.6K

05.11BUY

92,198

ARKKClose$14.42Est. total$1.3M

05.08BUY

26,324

ARKKClose$14.09Est. total$370.9K

05.07BUY

102,247

ARKKClose$13.71Est. total$1.4M

05.06BUY

28,220

ARKKClose$13.85Est. total$390.8K

05.05BUY

214,225

ARKKClose$13.31Est. total$2.9M

05.01BUY

140,963

ARKKClose$13.26Est. total$1.9M

04.29BUY

2,407,396

ARKG · ARKKClose$12.44Est. total$30.0M

04.28BUY

596,171

ARKG · ARKKClose$13.20Est. total$7.9M

1 / 14

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

12,467,399

Portfolio Weight

1.1%

in ETF 1.81%

Est. Value

$137M

30D Net

+$9M

Ray DalioBridgewater Associates

New Buy

223,166

Portfolio Weight

0.01%

Est. Value

$2M

Change

New position

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Analyst Targets

avg.

$23.94

vs Current ▲ +92.1% upside

Current$12.46

Low ~ High$8.00 ~ $61.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

Evercore ISI Group

Outperform

$24.00

+92.62%

$11.94

Upgrade

2026-08-07

Wolfe Research

Underperform

$9.00

-27.77%

$11.86

Downgrade

2026-07-16

Wedbush

Neutral

$17.00

+36.44%

$14.22

Maintain

2026-07-10

Canaccord Genuity

Buy

$49.00

+293.26%

$14.55

Maintain

2026-06-16

Citizens

Market Outperform

$30.00

+140.77%

$14.92

Maintain

2026-06-15

1 / 4

Avg Target

$23.94

vs Current ▲ +92.1% upside

Buy

19 analysts

Strong Buy 1Buy 9Hold 6Sell 2Strong Sell 1

Low $8.00

Current $12.46

High $61.00

Firm	Position	Target	Upside	Close	Action	Date
Evercore ISI Group	Outperform	$24.00	+92.62%	$11.94	Upgrade	26.08.07
Wolfe Research	Underperform	$9.00	-27.77%	$11.86	Downgrade	26.07.16
Wedbush	Neutral	$17.00	+36.44%	$14.22	Maintain	26.07.10
Canaccord Genuity	Buy	$49.00	+293.26%	$14.55	Maintain	26.06.16
Citizens	Market Outperform	$30.00	+140.77%	$14.92	Maintain	26.06.15

1 / 4

Price Information

Previous Close$12.84

Open$12.65

Day Range$12.65 - $13.13

52-Week Range$7.95 - $28.25

1-Year Change12.83%

Trading Volume

Volume2,807,461

Avg Volume (3mo)4,965,812

Valuation

Market Cap1.8B

Book Value$5.20

Shares Outstanding140,126,693

Financials

Revenue (TTM)59.5M

Net Income-399,975,008

EPS$-3.34

EBITDA-414,400,000

Profitability

P/E Ratio-

P/B Ratio2.47

Return on Equity (ROE)-55.44%

Return on Assets (ROA)-30.14%

Profit Margin0.00%

EV/EBITDA-3.46

Beta1.79

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)67.39

Company Overview

Intellia Therapeutics is a clinical-stage gene editing company developing curative treatments for genetic diseases and cancers. Their main products are in vivo gene editing therapies like NTLA-2001 for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema, alongside engineered cell therapies. The company is a leader in applying CRISPR/Cas9 technology to create novel genomic medicines.

P/B

2.47

Price-to-Book

ROE

-55.4%

Persistent loss

Beta

1.79

High volatility

RSI(14)

67.4

Neutral zone

AI-generated summary. Not investment advice.

Intellia Therapeutics, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks